title: [A case of long-term survivor with multiple pulmonary metastases of HCC after hepatic resection].
abstract: A 52-year-old male was admitted to our hospital with huge hepatoma of the right lobe. He underwent a right lobectomy of the liver in July 1999. After five months from the surgery, multiple recurrences in the liver and lung were revealed with Computed tomography (CT). TAE was performed for intrahepatic recurrence and a combination therapy, consisting of UFT and interferon-alpha, was started for pulmonary metastasis. Then 5-FU/CDDP/interferon-alpha therapy was given in 2001 and TS-1/interferon-beta therapy was given thereafter in 2002. Consequently, the patient survived for 31 months with no disturbance in quality of life. No intrahepatic recurrence was also detected during the survival period. It was suggested that a good prognosis may be expected, even in the HCC case with distant metastasis after hepatic resection, if the primary cite was curatively treated.
authors.affiliation: Dept. of Surgery and Clinical Oncology, Graduate School of Medicine, Osaka University.
authors.forename: Masato
authors.initials: M
authors.lastname: Nakamura
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Nagano
authors.forename: Masato
authors.initials: M
authors.lastname: Sakon
authors.forename: Motoi
authors.initials: M
authors.lastname: Kondo
authors.forename: Tameyoshi
authors.initials: T
authors.lastname: Yamamoto
authors.forename: Hideo
authors.initials: H
authors.lastname: Ota
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Wada
authors.forename: Bazarragchaa
authors.initials: B
authors.lastname: Damdinsuren
authors.forename: Yubo
authors.initials: Y
authors.lastname: Yang
authors.forename: Shigeru
authors.initials: S
authors.lastname: Marubashi
authors.forename: Atsushi
authors.initials: A
authors.lastname: Miyamoto
authors.forename: Keizo
authors.initials: K
authors.lastname: Dono
authors.forename: Koji
authors.initials: K
authors.lastname: Umeshita
authors.forename: Shoji
authors.initials: S
authors.lastname: Nakamori
authors.forename: Morito
authors.initials: M
authors.lastname: Monden
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000473:pathology* / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage; D004338:Drug Combinations; D005472:Fluorouracil / Q000008:administration & dosage; D006498:Hepatectomy; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage; D016899:Interferon-beta / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000473:pathology* / Q000601:surgery; D008175:Lung Neoplasms / Q000401:mortality / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D010094:Oxonic Acid / Q000008:administration & dosage; D011725:Pyridines / Q000008:administration & dosage; D005641:Tegafur / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D014498:Uracil / Q000627:therapeutic use
chemical_list: D004338:Drug Combinations; D016898:Interferon-alpha; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D014498:Uracil; D010094:Oxonic Acid; D016899:Interferon-beta; D002945:Cisplatin; D005472:Fluorouracil